Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01870388 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01870388 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 16 participants.
The verdict
NCT01870388, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll. The study will last about 7 days for each participant, not including screening.
Interventions
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01870388
The ClinicalTrials.gov registry entry for NCT01870388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Baricitinib is the first listed.
NCT01870388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01870388 about?
NCT01870388 is a clinical study titled "A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease". The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll. The study will last about 7 days for each participant, not including sc...
What is the current status of trial NCT01870388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01870388?
The interventions under investigation include: Baricitinib (DRUG).
Who is sponsoring clinical trial NCT01870388?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.